Veracyte Past Earnings Performance

Past criteria checks 0/6

Veracyte's earnings have been declining at an average annual rate of -20.5%, while the Biotechs industry saw earnings growing at 14.5% annually. Revenues have been growing at an average rate of 29.4% per year.

Key information

-20.5%

Earnings growth rate

-10.0%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth rate29.4%
Return on equity-7.1%
Net Margin-20.6%
Last Earnings Update31 Dec 2023

Recent past performance updates

Recent updates

Lacklustre Performance Is Driving Veracyte, Inc.'s (NASDAQ:VCYT) Low P/S

Apr 18
Lacklustre Performance Is Driving Veracyte, Inc.'s (NASDAQ:VCYT) Low P/S

A Look At The Intrinsic Value Of Veracyte, Inc. (NASDAQ:VCYT)

Mar 18
A Look At The Intrinsic Value Of Veracyte, Inc. (NASDAQ:VCYT)

Veracyte Percepta Genomic Sequencing Classifier demonstrates accuracy in lung cancer risk

Jul 13

Veracyte: Not A Healthy Diagnosis

May 12

Valuing Veracyte Stock

Oct 03

Revenue & Expenses Breakdown
Beta

How Veracyte makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqGM:VCYT Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 23361-7419254
30 Sep 23343-5018550
30 Jun 23329-2918447
31 Mar 23311-3017441
31 Dec 22297-3717141
30 Sep 22284-4318740
30 Jun 22268-4917737
31 Mar 22251-4817130
31 Dec 21220-7618030
30 Sep 21187-7311924
30 Jun 21157-6310520
31 Mar 21123-658917
31 Dec 20117-358817
30 Sep 20113-348617
30 Jun 20113-318723
31 Mar 20122-228911
31 Dec 19120-138315
30 Sep 19116-8770
30 Jun 19109-1273-7
31 Mar 19101-16671
31 Dec 1892-236515
30 Sep 1886-286315
30 Jun 1880-316115
31 Mar 1876-325914
31 Dec 1772-31551
30 Sep 1771-275314
30 Jun 1772-265215
31 Mar 1768-295216
31 Dec 1665-315215
30 Sep 1661-355315
30 Jun 1655-385215
31 Mar 1652-365013
31 Dec 1550-344813
30 Sep 1548-344813
30 Jun 1545-334711
31 Mar 1542-304210
31 Dec 1438-293910
30 Sep 1433-27348
30 Jun 1429-26298
31 Mar 1425-25278
31 Dec 1322-26258
30 Sep 1320-25238
30 Jun 1317-23217
31 Mar 1315-21197

Quality Earnings: VCYT is currently unprofitable.

Growing Profit Margin: VCYT is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: VCYT is unprofitable, and losses have increased over the past 5 years at a rate of 20.5% per year.

Accelerating Growth: Unable to compare VCYT's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: VCYT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.9%).


Return on Equity

High ROE: VCYT has a negative Return on Equity (-7.13%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.